Pharmaceutical pay-for-delay agreements, the precise term is reverse payment patent settlements, sit at the intersection of Hatch-Waxman exclusivity mechanics, branded […]
Pay-for-Delay Pharma Settlements: The Complete Antitrust & IP Strategy Guide Read Post »
Section 1: What an Authorized Generic Actually Is (And Why Definitions Matter for Deal Modeling) 1.1 The Core Definition An
Here’s a summary of a new article that used DrugPatentWatch data: NIH Funding for Patents That Contribute to Market Exclusivity
DrugPatentWatch reveals NIH funding for patents Read Post »
For IP teams, portfolio managers, R&D leads, and institutional investors who need more than an overview. A pharmaceutical patent is
Pharma Patent Filing Strategies That Maximize Exclusivity: The Complete IP Playbook Read Post »
On NPR’s All Things Considered, Sydney Lupkin asked DrugPatentWatch if drug patents could be used to identify injector pens which
NPR and DrugPatentWatch – Can drug injector pens be swapped? Read Post »
1. Why the 505(b)(2) Pathway Exists and Who It Rewards The Hatch-Waxman Design Intent The Drug Price Competition and Patent
The 505(b)(2) Playbook: Cut Dev Time, Lock In Exclusivity, and Outmaneuver Generics Read Post »
DrugPatentWatch has been named to Genetic Engineering News‘ Best of the Web list. The review by Genetic Engineering News profile
DrugPatentWatch named “Best of the Web” by Genetic Engineering News Read Post »
The innovation-exclusivity-reinvestment cycle The fundamental economic engine of the innovator pharmaceutical industry functions through a self-sustaining loop. This cycle begins
Sell the use, not the molecule Read Post »
1. What Excipients Actually Do (and Why the ‘Inactive’ Label Is Costing You Sales) The phrase ‘inactive ingredient’ is a
Drug Patent Intelligence for Excipient Companies: The Complete Revenue Growth Playbook Read Post »
Sign in or create a free account to read this DrugPatentWatch article
